3d Printer User Data 3d Print Industry

Written report Overview

The global 3D bioprinting market size was valued at USD one.vii billion in 2021 and is expected to expand at a compound annual growth charge per unit (CAGR) of 15.8% from 2022 to 2030. The growth of this market is attributed to a limited number of organ donors, and an increasingly aging population with chronic respiratory disease. Rising R&D investment, technological advocacy, and increasing incidence of chronic diseases are other vitally impacting attributes likely to boost market place growth during the forecast menses. The 3D printing community has responded to the COVID-19 crisis, pledging to support the production of vital medical equipment for hospitals grappling with this pandemic.

The recent COVID-xix pandemic has taken hold over the globe, with even the healthcare systems being overburdened. Hence, as a reaction to the rising cases of coronavirus, various 3D Bioprinting communities are responding to the worldwide crises past offer their respective skills to ease the brunt on the supply chain and governments. As the cases of COVID-19 are increasing solar day by day, there has been a shortage of materials for the medical professionals as well as for the full general public. One of the biggest problems is the lack of availability of test kits for COVID-19. Hence, various 3D bioprinting companies are manufacturing 3D printers and related software on a large calibration. For example, Formlabs company based in Massachusetts, U.South. reportedly manufactures 100,000 nasal swabs for COVID-19 testing each day. Due to the ever-increasing cases of COVID-19, the demand for 3D bioprinters is increasing and the global 3D bioprinting market is slated to showcase exponential growth.

The coronavirus pandemic has also accelerated the development of drug and vaccine testing, equally scientists are harnessing new technologies for safety testing in patients after preclinical trials are completed. With the always-increasing cases of COVID-19, the medical world is also facing a shortage of respirators and ventilators. The 3D bioprinting technology is helping in manufacturing respirators and ventilators to overcome the shortage of these devices.

Recently CLECELL, a 3D bioprinting company, created a respiratory epithelium model using their proprietary 3D printer U-FAB, along with other bioprinting technologies. Respiratory epithelium is a type of tissue that lines most of the respiratory tract. This epithelium acts as a bulwark to pathogens and foreign particles. However, it besides prevents infection and tissue injury with the help of the mucociliary elevator. Hence, with increasing incidences of need for this respiratory epithelium model, the market for 3D bioprinting is anticipated to witness growth. Attributable to such innovations, the market is expected to witness higher growth during the forecast period.

Many biotherapeutic companies are using 3D bioprinting engineering in lodge to accelerate COVID-19 research. For example, Viscient Biosciences used 3D bioprinting technology to create lung tissue which supports viral infectivity enquiry and helps in searching for effective therapy confronting SARS-CoV-2, the novel coronavirus which causes COVID-19. The Wyss Constitute at Harvard Academy has designed a fully injection-molded nasopharyngeal swab in collaboration with healthcare, industrial partners, and other research institutes.

3D bioprinting is witnessing demand on a big scale with the increasing spread of the COVID-19 infection. Hence, many pharmaceutical and biopharmaceutical participants are coming forward to assistance healthcare workers, physicians, and scientists in all possible means. For example, Stratasys, which is one of the leading manufacturers of 3D printers in America, has manufactured face shields with the help of a 3D bioprinter. Until March 2020, they shipped 100,000 face shields in the U.S.

Technology Insights

The inkjet-based segment accounted for the largest acquirement share of 36.0% in 2021, as information technology enables the printing of circuitous living organs or tissues on the culture substrates with the help of biomaterials as bio-inks. The wide adoption of inkjet-based press in the medical field is contributing to the segment’s growth. This work presents the research trends in inkjet printing equally a bio-applicable technology, especially in the fields of tissue engineering science and drug delivery systems. This segment is anticipated to observe pregnant growth during the forecast period, owing to its increasing demand and higher reliability.

The magnetic levitation segment is projected to expand with the fastest CAGR of 14.2% during the forecast period. The lucrative growth can be attributed to the price-efficiency associated with the technology. Magnetic levitation engineering is expected to solve more than lxxx.0% of the errors in 3D bioprinting with its advanced features, enhanced speed, and precision. These bioprinters are likewise used for toxicity screening, vascular muscle printing, and human cell regeneration. For instance, BioAssay has developed a tissue-like construction, with the help of magnetic levitation-based devices. The magnetic levitation-based devices are about likely to witness sluggish growth during the forecast menstruum, owing to a rapid increment in usage of newer technologies.

Application Type Insights

The medical segment dominated the market place by application in 2021, with a share of 36.8%, and is anticipated to grow with a CAGR of 15.six% during the forecast period. The vast usage of medical pills to cure various chronic diseases is propelling the growth of the market for 3D bioprinting. Moreover, the growing need for medicines and cost-efficient application of bio-drugs using this technology is further driving the segment. With the increasing number of participants in the pharmaceutical manufacture, the need for medical pills is increasing. Millions of people globally are regular users of capsules and medicinal pills. Hence, this segment is expected to witness lucrative growth over the forecast flow.

The tissue and organ generation sub-segment is expected to grow with the fastest CAGR of xv.6% in the market during the forecast period. 3D bioprinting is near widely used to regenerate medicine to address the need for organs and tissue regeneration suitable for transplantation. With the rising incidence of the COVID-19 illness, the demand for tissue and organ generation is increasing. Due to this reason, the tissue and organ generation segment is expected to witness exponential growth during the forecast period. The increasing number of COVID -nineteen cases globally is expected to provide new growth avenues for the fundamental market players. Various players in the marketplace for 3D bioprinting are engaged in developing new techniques that can overcome this pandemic effect and produce a vaccine to care for COVID-xix.

Regional Insights

In Asia Pacific, the market accounted for a revenue share of 23.7% of the 3D bioprinting manufacture in 2021 and is expected to continue its authority during the forecast period. Nihon and Prc accounted for the largest revenue share in the region due to the increasing incidence of COVID-19 cases and ascension investment of government in R&D. As per the Worldometer Written report 2021, around 87,706 agile cases of COVID-19 were reported in China until thirteen January 2021. Moreover, the increasing mortality rate due to COVID-19 and shortage of organ donors are further predictable to drive the market for 3D bioprinting in this region.

In North America, the market captured a acquirement share of 31.6% in 2021 and is expected to lead throughout the forecast period. The increasing incorporation of IT in the healthcare industry is estimated to stimulate the growth of the market over the forecast menstruation. Equally per the Worldometer Report 2021, around 23,369,732 active cases of COVID-19 were reported in the U.South. alone until 13 January 2021. In that location are currently over fifty vaccine candidates under trial. The government is spending more on research and development, in guild to come upwardly with a vaccine for this condition. Due to this reason, at that place is an increasing demand for 3D bioprinting, every bit this technology has been reconnoitered for drug testing and organ transplantation.

Competitive Insights

Central companies are stressing research and development to develop technologically advanced applications to gain a competitive edge. For example, in November 2019, CELLINK developed the most advanced 3D bioprinting device, Bio X6, as well as Lumen X, which produces vascular structures. Likewise, Fluicell, a  Sweden-based company launched a high-resolution bioprinting engineering science in both 3D and 2d forms, known as Biopixlar. This 3D bioprinter creates a complex tissue-similar structure through which the positioning of individual cells tin can be controlled. It consists of some novel feature that allows users to command the organisation.

Companies are engaging in partnerships, mergers, and acquisitions, aiming to strengthen their awarding portfolio and manufacturing capacities and provide competitive differentiation. For example, in Nov 2019, BASF GmbH caused Sculpteo, a 3D printing service provider. This acquisition is anticipated to aid BASF to market and establish new industrial 3D press materials more quickly. Some of the prominent players in the 3D bioprinting market include:

• EnvisionTEC, Inc.

• Organovo Holdings, Inc.

• Inventia Life Science PTY LTD

• Poietis

• Vivax Bio, LLC

• Allevi

• Cyfuse Biomedical K.Chiliad.

• 3D Bioprinting Solutions

• Cellink Global

• Regemat 3D Southward.L.

3D Bioprinting Market Report Telescopic

Segments Covered in the Report

This report forecasts revenue growth at global, regional & land levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this written report, Grand View Research has segmented the global 3D bioprinting market place report based on engineering, application, and region:

• Engineering Outlook (Revenue, USD 1000000, 2017 – 2030)

  • Magnetic Levitation

  • Inkjet-based

  • Syringe-based

  • Laser-based

  • Others

• Application Outlook (Acquirement, USD Million, 2017 – 2030)

  • Medical

    • Tissue and organ generation

    • Medical pills

    • Prosthetics and implants

    • Others

  • Dental

  • Biosensors

  • Consumer/Personal Product Testing

  • Bioinks

  • Food and Animal Product

• Regional Outlook (Revenue, USD Million, 2017 – 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.Chiliad.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • Mainland china

    • Bharat

    • Thailand

    • Republic of korea

  • Latin America

    • Brazil

    • Mexico

    • Argentine republic

    • Columbia

  • Heart East & Africa

    • Southward Africa

    • Kingdom of saudi arabia

    • UAE